Can GLP-1 Drugs Help Ulcerative Colitis?

Researchers at West Virginia University reported on August 21, 2026 that adults with ulcerative colitis who started a GLP-1 receptor agonist for metabolic reasons were more likely to reach symptomatic remission than matched patients who did not^[1]. At 12 weeks, 66.7% of the GLP-1 group reached remission versus 25.3% of the matched controls. The finding is an observational signal, not evidence that any GLP-1 drug treats ulcerative colitis, and no GLP-1 receptor agonist is approved for that indication anywhere we cover.

What the study actually found

The retrospective matched cohort study drew on electronic health records from 2022 through 2024. It matched 150 adults with ulcerative colitis who started a GLP-1 receptor agonist for a metabolic reason (weight or type-2 diabetes) and stayed on it for at least 12 weeks against 150 similar patients who did not start one. Two drugs made up the GLP-1 group: semaglutide and liraglutide. The triage note attached to this brief flagged semaglutide alone, but the actual cohort included both, and semaglutide performed better than liraglutide inside the study (72.5% remission versus 60%).

Remission rates separated early and widened over time: 34.7% versus 15.3% at 4 weeks, 54.7% versus 18.0% at 8 weeks, and 66.7% versus 25.3% at 12 weeks^[1]. Mean partial Mayo scores, a standard measure of ulcerative colitis symptom severity, fell from 5.8 to 2.1 in the GLP-1 group compared with a smaller drop to 4.6 in controls. In a subset that had a follow-up colonoscopy, 58% of the GLP-1 group showed endoscopic remission versus 38% of controls. After adjusting for other factors, GLP-1 use remained independently associated with remission (adjusted odds ratio 5.90).

This is not an approved ulcerative colitis treatment

Semaglutide is licensed as Ozempic and Rybelsus for type-2 diabetes and as Wegovy for chronic weight management^[2]. Liraglutide carries similar diabetes and weight-management approvals under different brand names. Neither drug carries a regulatory approval for ulcerative colitis or any other inflammatory bowel disease in the EU, UK or US. The patients in this study were prescribed a GLP-1 drug for a metabolic reason, not for their bowel disease, and the remission benefit showed up as a secondary observation. That distinction matters: using these drugs specifically to treat ulcerative colitis would be off-label prescribing, a decision for a gastroenterologist to make on a case-by-case basis, not something the study or this article recommends.

Why researchers think this connection might exist

GLP-1 receptor agonists have documented anti-inflammatory effects beyond their metabolic actions. A 2024 review in Therapeutic Advances in Endocrinology and Metabolism describes how the drug class modulates immune cell signaling and the NF-kB pathway (a signaling route that turns on many of the genes driving inflammation), which lowers markers of systemic inflammation in several disease models^[3]. A separate systematic review published in Alimentary Pharmacology & Therapeutics in January 2026 pooled 14 mostly retrospective studies of GLP-1 receptor agonists in people with inflammatory bowel disease and found the drugs were not associated with more disease flares, alongside observational signals for reduced steroid use and fewer hospitalizations^[4]. That review also noted that ten of the fourteen included studies reported meaningful reductions in body weight or BMI among patients with inflammatory bowel disease, which is the metabolic effect the drugs are actually approved for. Weight loss itself may also play a role, since obesity is linked to more severe inflammatory bowel disease courses in some patients. None of this establishes that GLP-1 receptor agonists directly treat ulcerative colitis. It explains why the WVU finding is plausible rather than a surprise, and why researchers are now asking for a prospective trial designed around the bowel-disease outcome instead of finding it as a side observation.

What this study cannot tell us

A matched retrospective cohort shows association, not cause. Patients were not randomly assigned to receive a GLP-1 drug, so anything that differed between the two groups before treatment, such as disease severity, weight, diet, or how closely a patient was monitored, could explain part of the remission gap rather than the drug itself. Weight loss and improved metabolic health are themselves linked to milder disease courses in some patients, and the study cannot fully separate that effect from a direct anti-inflammatory action. The authors also relied on partial Mayo scores from records rather than a prospective, blinded assessment, and the endoscopic-remission subgroup was smaller than the full cohort. Single-centre electronic health record studies can also carry selection bias: clinicians may have been more comfortable prescribing a GLP-1 drug to patients who already looked stable on other fronts. The systematic review cited above reached a similar conclusion for the wider literature: the observational evidence is encouraging, but prospective, controlled trials are needed before anyone can call GLP-1 receptor agonists a treatment for ulcerative colitis.

Practical context

If you have ulcerative colitis and are also being considered for a GLP-1 receptor agonist for weight or diabetes management, this study is a reasonable thing to bring up with your gastroenterologist, not a reason to seek one out on your own for your bowel disease. For background on how semaglutide is regulated and who can prescribe it, see our semaglutide regulation overview. We will keep tracking this line of research as more prospective trials read out.